CSL's largest blood products customer is the USA, its also its largest blood collection country. EU is (or was, don't quote me) the largest region for distribution of its flu vaccine, which it dominates the market by +70%. CSL are also extremely experienced at running successful P3 trials. So its not out of the relms if possibility.
That said, I agree its not a perfect match and a US big pharma would be a better suitor. However CSL could possibly be a better bodyguard to hostile takeover, if needed, than the "bank" that PR mentioned they would turn to in that situation.
Joint Venture, page-6
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.015(4.84%) |
Mkt cap ! $103.1M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 30.5¢ | 29.5¢ | $86.19K | 286.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 70151 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 18600 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |